Navigation Links
OXiGENE Abstracts Published in ASCO Program

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 1, 2007 - OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today the publication of two abstracts in the 2007 Annual Meeting program distributed this afternoon at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

The first abstract reports for the first time full data from a randomized Phase II trial of Combretastatin A4 Phosphate / CA4P (trademarked by OXiGENE as ZYBRESTAT(TM)) in combination with paclitaxel and carboplatin. In the abstract, lead author Dr. Wallace L. Akerley of the Huntsman Cancer Institute reports that the two dose regimens of CA4P studied, 45 mg/m2 and 63 mg/m2 in combination with paclitaxel and carboplatin, were well tolerated, demonstrated anti-tumor activity and reduced tumor blood flow by 46% and 19%, respectively. Tumor responses were observed and were similar between both dose groups, and the best overall response through cycle 6 was three partial responses (PR) and six stable disease (SD) responses as measured by RECIST criteria. Notably, the two patients with anaplastic thyroid cancer (ATC), the lead indication for ZYBRESTAT, achieved the greatest reductions in tumor blood flow (Ktrans of 73% and 79%). The study enrolled 13 patients with advanced imageable malignancies, and imaging evaluations were carried out using DCE-MRI, a standard imaging modality used to evaluate tumor blood flow and perfusion. DCE-MRI evaluations were performed prior to and 24 hours following the first dose of ZYBRESTAT. Interim data for this study was previously reported in September 2006 at The Tumor Microenvironment 10th International Workshop.

The second abstract reports for the first time initial data from early dosing cohorts in a Phase I study of OXi4503 in patients with advanced solid tumors. Lead author Dr. Danie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
(Date:9/17/2014)... September 17, 2014 ... has shown positive data in a Phase 2a proof ... , Glenmark Pharmaceuticals today announced ... 1 (TRPA1) antagonist, GRC 17536 has shown positive data ... proof of concept study conducted on 138 patients in ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... New study finds patients who opt for surgery have decreased pain, ... with the spine disease called degenerative spondylolisthesis * ... pain over time compared to those who do not have surgery, ... The Journal of Bone and Joint Surgery ...
... GAITHERSBURG, Md., June 1 Overall survival data in ... GenVec,s ongoing Phase III Pancreatic Cancer Clinical Trial with ... Society of Clinical Oncology Annual Meeting in Orlando, FL. ... ) , , The poster ...
Cached Medicine Technology:Back to Normal: Surgery Improves Outcomes for Spine Patients 2Back to Normal: Surgery Improves Outcomes for Spine Patients 3Back to Normal: Surgery Improves Outcomes for Spine Patients 4TNFerade(TM) Phase III Data Presented at ASCO 2TNFerade(TM) Phase III Data Presented at ASCO 3
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... uncovered a key factor to explain why antibiotic-resistant bacteria can ... DNA called plasmids appear to be the culprit. They can ... and some carry a gene that makes bacteria drug-resistant, a ... carry an antibiotic-resistant gene to a class of antibiotic called ...
(Date:9/17/2014)... able to reduce the need for invasive biopsies in ... lupus. , In a new study, researchers developed a ... kidney inflammation to interstitial fibrosis, scarring in ... biopsy is the only existing way to reach a ... The model could also be used to monitor the ...
(Date:9/17/2014)... September 17, 2014 Today, Blue ... million in third-quarter grantmaking. This body of grants aims ... spreading innovations in care delivery, as well as to ... uninsured. Grants will also strengthen the capacity of both ... responsive and create new entry points for domestic violence ...
(Date:9/17/2014)... 2014 In a country where 77% ... a regular basis, how can Americans find healthy and ... Hyland’s Stress Challenge , a 5-day interactive journey to ... life. From September 29th – October 3rd, the ... relating to specific topics that promote natural solutions for ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. ... confirmed cases of Enterovirus D68, the severe respiratory illnesses ... officials report. Alabama, Colorado, Illinois, Indiana, Iowa, Kansas, ... have 130 laboratory-confirmed cases of Enterovirus D68, according to ... The virus, part of the family of viruses that ...
Breaking Medicine News(10 mins):Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Blue Shield of California Foundation Awards $5 Million in Third-Quarter Grants 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:12 States Now Reporting Severe Respiratory Illness That Targets Kids 2Health News:12 States Now Reporting Severe Respiratory Illness That Targets Kids 3
... , WEDNESDAY, Feb. 9 (HealthDay News) -- The number ... attempts swings sharply depending on what month it is, a ... for men aged 50 and older, while there was little ... the report from the Substance Abuse and Mental Health Services ...
... many patients realise that diabetes can affect their kidneys is ... multi-cultural study in the March issue of the Journal ... to 48 patients with diabetes attending specialist renal services in ... risks posed by the disease was very low. ...
... Researchers from the Hospital Virgen de las Nieves of ... frequent mutations in the gene KCNH2 in patients with long ... cardiac ionic channels that approximately affects one in every 2,500 ... trigger sudden death. This condition usually affects children and adolescents, ...
... Sciences Discovery Fund (LSDF) today announced nearly $600,000 in ... the diagnosis and management of major health conditions. ... producing novel tests to diagnose or monitor disease. Jane ... a Washington-based company, will adapt a novel air sampling ...
... HealthDay Reporter , TUESDAY, Feb. 8 (HealthDay News) -- Men ... bearing children with congenital problems such as a cleft palate compared ... research. But the overall risk was low, researchers from Sweden ... of the National Cancer Institute . And the findings ...
... at the University at Buffalo have devised two new ... important molecules from losing their shape and degrading in ... the development of peptide-based drugs against diseases including cancer. ... than existing techniques, one of which employs an expensive ...
Cached Medicine News:Health News:Males' Drug-Related Suicide Attempts Vary by Month 2Health News:Experts call for greater awareness of the links between diabetes and kidney disease 2Health News:Experts call for greater awareness of the links between diabetes and kidney disease 3Health News:Researchers identify the genotype of disorders causing cardiac sudden death syndrome 2Health News:Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies 2Health News:Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies 3Health News:Birth Defect Risk Slightly Higher for Kids of Male Cancer Survivors 2Health News:Birth Defect Risk Slightly Higher for Kids of Male Cancer Survivors 3Health News:New techniques for stapling peptides could spur development of drugs for cancer 2
... Pulse Oximeter monitors SpO2, pulse ... is designed to provide fast, ... The device rejects spontaneous motion ... operator of excess artifacts and ...
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
Halogen-free immersion oil based on ester oil....
Immersion Oil, 150 cs...
Medicine Products: